Mental Health Advance Directives: Planning for Psychiatric Crises

Mental health advance directives are legal documents that allow individuals with psychiatric conditions to record treatment preferences and designate decision-making authority before a crisis renders them unable to communicate those preferences. This page covers the definition and legal classification of these instruments, how they function within the US healthcare and legal framework, the clinical situations in which they activate, and the boundaries that govern their enforceability. Understanding these documents is relevant to anyone navigating conditions such as bipolar disorder, schizophrenia, or recurrent suicidality and crisis episodes, where capacity fluctuates predictably.

Definition and scope

A mental health advance directive (MHAD) is a subset of advance directive law applied specifically to psychiatric treatment. Unlike a general healthcare advance directive — which typically addresses end-of-life medical decisions — an MHAD is designed to govern psychiatric interventions during episodes of incapacity caused by acute mental illness rather than terminal medical decline.

Two primary instrument types exist within this category:

1. Psychiatric Advance Directive (PAD) — A written instruction document in which the individual specifies which psychiatric treatments are acceptable or unacceptable (e.g., particular medications, electroconvulsive therapy, inpatient hospitalization settings). The PAD may stand alone.

2. Healthcare Proxy / Durable Power of Attorney for Mental Health — An instrument that designates a named surrogate decision-maker (agent) with authority to make psychiatric treatment decisions on behalf of the principal when capacity is lost. This may be combined with instruction content or issued separately.

The legal status of MHADs is governed at the state level. As of the framework established by the National Resource Center on Psychiatric Advance Directives (NRC-PAD), 27 states had enacted statutes that explicitly authorize psychiatric advance directives as of the most recent NRC-PAD state survey (NRC-PAD State Survey). The remaining states may permit general durable power of attorney instruments to apply to psychiatric decisions, but the coverage is uneven.

Federal policy context comes from the Substance Abuse and Mental Health Services Administration (SAMHSA), which classifies PADs as a recovery-oriented tool aligned with its National Mental Health Strategy. SAMHSA's 2019 publication Psychiatric Advance Directives: Getting Started provides a framework practitioners and systems planners reference (SAMHSA).

How it works

An MHAD follows a structured execution process that mirrors general advance directive law, with psychiatric-specific requirements layered on top.

Execution steps:

1. Drafting — The principal, while possessing decision-making capacity, documents treatment preferences and/or designates an agent. The document typically must be written, not oral.
2. Witnessing and notarization — Most state statutes require 2 adult witnesses and/or notarization. Witnesses are generally prohibited from being the designated agent, a treating provider, or an heir to the principal's estate.
3. Capacity attestation — Some state statutes require a clinician, attorney, or qualified professional to attest that the principal had decision-making capacity at the time of signing.
4. Distribution — Copies are provided to the designated agent, treating psychiatrist, primary care provider, and the principal's chosen inpatient psychiatric facility if applicable. NRC-PAD recommends filing a copy in the medical record and with any crisis services the individual uses.
5. Registration — Several states maintain advance directive registries. The Uniform Health-Care Decisions Act (UHCDA), adopted in modified form by a subset of states, provides a standardized framework for validity across jurisdictions.
6. Activation — The document becomes operative when a qualified clinician determines the principal lacks decision-making capacity. Standards for that determination are typically drawn from state mental health code or the principal's own document.
7. Review and revocation — The principal retains the right to revoke the directive at any time while possessing capacity. Revocation must generally be communicated to treating providers and the named agent.

A key contrast between PADs and general medical advance directives involves the override question. General healthcare proxies rarely authorize treatment refusals that would result in immediate death. MHADs carry a parallel complication: in most jurisdictions, clinicians may override a PAD when a court has ordered treatment, when the patient presents a danger to self or others, or when following the directive would be contrary to the applicable standard of care — a clause defined under individual state mental health code rather than any uniform federal standard.

Psychiatric medication classes preferences are among the most frequently documented elements in PADs, as medication responses and side-effect histories are highly individual.

Common scenarios

MHADs are most practically relevant in three recurring clinical contexts:

Bipolar disorder with psychotic features — Individuals who have experienced prior manic or mixed episodes during which they refused hospitalization or specific medications can document preferences established during euthymic phases. This prevents retrospective disputes about whether prior refusals reflected genuine preference or incapacity.

Schizophrenia and treatment resistance — Individuals with chronic psychotic illness who have established medication regimens that work — but who may refuse those medications during decompensation — can specify preferred antipsychotics and authorize their agent to consent to administration. See the reference entry on antipsychotic medications for classification context.

PTSD and trauma-informed care preferences — Individuals with PTSD and trauma-related disorders may use MHADs to document specific procedural preferences (e.g., prohibition on physical restraint, gender of treating staff, preferred de-escalation approaches) that reduce retraumatization risk during crisis admissions. The Substance Abuse and Mental Health Services Administration's Trauma-Informed Care in Behavioral Health Services (TIP 57) specifically identifies advance directives as a trauma-informed planning mechanism.

Involuntary hold prevention — A completed PAD does not automatically prevent an involuntary psychiatric hold, but it informs clinical decision-making and emergency department staff of documented preferences, which can accelerate voluntary admission and reduce coercive intervention when criteria are borderline.

Decision boundaries

MHADs operate within defined legal and clinical limits. Misunderstanding these limits is a documented source of conflict between patients, agents, and treating providers.

What an MHAD can direct:

• Preferred or refused psychiatric medications (by name or class)
• Preferred or refused settings for psychiatric care (specific hospitals, avoidance of certain facilities)
• Consent to or refusal of specific procedures, including electroconvulsive therapy
• Named agent with defined scope of authority
• Notification preferences (who is contacted during a crisis)
• Religious, cultural, or personal care preferences

What an MHAD cannot override:

• A court-ordered treatment order under state mental health law
• Emergency intervention required to prevent imminent danger to self or others (the standard defined under most state involuntary commitment statutes)
• Treatment the clinician determines is medically necessary when the directive's instruction creates an unacceptable clinical risk, per the treating facility's ethics and legal review process

The Americans with Disabilities Act (ADA), administered by the U.S. Department of Justice, does not independently govern MHAD enforceability, but ADA principles bear on how psychiatric advance directives interact with disability rights frameworks in institutional settings (U.S. Department of Justice, ADA).

HIPAA, administered by the HHS Office for Civil Rights, governs disclosure of information to the named agent once a directive activates. The agent's authority to receive protected health information is bounded by what the directive and applicable state law specify — not by HIPAA's default privacy rules alone (HHS Office for Civil Rights, HIPAA).

Capacity assessment — the threshold event that activates an MHAD — does not have a single federal standard. The MacArthur Competence Assessment Tool for Treatment (MacCAT-T), developed by researchers at the MacArthur Research Network, is one of the most widely used structured instruments for this determination in psychiatric settings, though its use is not federally mandated.

The gap between what a directive specifies and what a provider is willing to honor remains a structural vulnerability in MHAD implementation. NRC-PAD research has documented that provider unfamiliarity with PAD content is a primary barrier to compliance, independent of legal status.

References

• National Resource Center on Psychiatric Advance Directives (NRC-PAD) — State Survey
• Substance Abuse and Mental Health Services Administration (SAMHSA)
• SAMHSA — Trauma-Informed Care in Behavioral Health Services, TIP 57
• U.S. Department of Justice — Americans with Disabilities Act (ADA)
• HHS Office for Civil Rights — HIPAA
• Uniform Law Commission — Uniform Health-Care Decisions Act (UHCDA)
• MacArthur Research Network on Mental Health and Law — MacCAT-T